Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-08
2008-04-08
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S062000, C546S014000
Reexamination Certificate
active
07354927
ABSTRACT:
This invention provides 6H-[1]benzopyrano[4,3-b]quinoline compounds having the formula I:The invention further provides compositions including the compounds, methods for the use of the compounds, and methods of preparation of the compounds.
REFERENCES:
patent: 3493579 (1970-02-01), Lyle et al.
patent: 3518258 (1970-06-01), von Strandtmann et al.
patent: 3518272 (1970-06-01), von Strandtmann et al.
patent: 3518273 (1970-06-01), von Strandtmann et al.
patent: 3541100 (1970-11-01), Ramirez et al.
patent: 3551565 (1970-12-01), Clarke et al.
patent: 3600375 (1971-08-01), Wang et al.
patent: 4418068 (1983-11-01), Jones
patent: 5318976 (1994-06-01), Luzzio et al.
patent: 5998402 (1999-12-01), Miller et al.
patent: 6110962 (2000-08-01), Wrobel et al.
patent: 2002/0140132 (2002-10-01), Guarr et al.
patent: 2002/0183310 (2002-12-01), Miller et al.
patent: 2003/0087955 (2003-05-01), Miller et al.
patent: 2003/0166643 (2003-09-01), Mcdevitt
patent: 2003/0171412 (2003-09-01), Malamas et al.
patent: 2003/0199570 (2003-10-01), Coghlan et al.
patent: 376166 (1990-07-01), None
patent: 2361642 (2001-10-01), None
patent: 2374412 (2002-10-01), None
patent: 63295579 (1988-01-01), None
patent: 63238079 (1988-04-01), None
patent: 1051092 (1982-07-01), None
patent: 264124 (1986-10-01), None
patent: WO 94/20869 (1994-09-01), None
patent: WO 95/06640 (1995-03-01), None
patent: WO 96/10015 (1996-04-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO 97/09348 (1997-03-01), None
patent: WO 98/45272 (1998-10-01), None
patent: WO 99/07847 (1999-02-01), None
patent: WO 89/02739 (1999-04-01), None
patent: WO 00/01716 (2000-01-01), None
patent: WO 00/59897 (2000-10-01), None
patent: WO 00/61230 (2000-10-01), None
patent: WO 00/62765 (2000-10-01), None
patent: WO 00/76529 (2000-12-01), None
patent: WO 01/24785 (2001-04-01), None
patent: WO 01/64665 (2001-09-01), None
patent: WO 01/72713 (2001-10-01), None
patent: WO 02/30407 (2002-04-01), None
patent: WO 02/46164 (2002-06-01), None
patent: WO 02/46168 (2002-06-01), None
patent: WO 02/051821 (2002-07-01), None
patent: WO 02/068548 (2002-09-01), None
patent: WO 03/044006 (2003-05-01), None
patent: WO 03/045930 (2003-06-01), None
patent: WO 03/050095 (2003-06-01), None
patent: WO 03/051863 (2003-06-01), None
patent: WO 03/061701 (2003-07-01), None
patent: WO 04/000817 (2003-12-01), None
patent: WO 2004/073610 (2004-09-01), None
patent: WO 2004/094400 (2004-11-01), None
patent: WO 2004/094401 (2004-11-01), None
patent: WO 2004/094451 (2004-11-01), None
patent: WO 2004/099122 (2004-11-01), None
patent: WO 2004/103973 (2004-12-01), None
patent: WO 2005/018636 (2005-03-01), None
patent: WO 2005/051972 (2005-06-01), None
patent: WO 2005/082880 (2005-09-01), None
patent: WO 2005/123757 (2005-12-01), None
Malecki, N. et al.: Synthesis of condensed quinolines and quinazolines as DNA ligands. Bioorg. & Medicnal Chem. vol. 12, pp. 641-647, Feb. 1, 2004.
Wright, G. et al.: A study of the catalytic reductive products of 2,3-dihydro-6-methoxy-3-(6-nitroveratrylidene)-4H-benzopyran-4-one. J. Heterocyc. Chem. vol. 13, pp. 1181-1185, 1976.
Al-Azzawi, “The menopause and its treatment in perspective,”Postgraduate Medical Journal(2001) 77:292-304.
Bhat et al., “A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids,”Journal of Steroid Biochemistry&Molecular Biology(1998) 67(3):233-240.
Black et al., “Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice ,”Life Sciences(1980) 26(17):1453-1458.
Brincat, “Hormone replacement therapy and the skin,”Maturitas(2000) 35(2):107-117.
Calvin, “Oestrogens and wound healing,”Maturitas(2000) 34(3):195-210.
Couse et al., “Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse,”Endocrinology(1997) 138(11):4613-4621.
Cowley et al., “Estrogen receptors alpha and beta form heterodimers on DNA,”Journal of Biological Chemistry(1997) 272(32):19858-19862.
Crandall, “Estrogen replacement therapy and colon cancer: a clinical review,”Journal of Women's Health&Gender-Based Medicine(1999) 8(9):1155-1166.
Edsall et al., “ERbeta ligands. Part 1: the discovery of ERbeta selective ligands which embrace the 4-hydroxy-biphenyl template,”Bioorganic&Medicinal Chemistry(2003) 11(16):3457-3474.
Epperson et al., “Gonadal steroids in the treatment of mood disorders,”Psychosomatic Medicine(1999) 61(5):676-697.
Finking et al., “[The effects of estrogen in the cardiovascular system],”Zeitschrift fur Kardiologie(2000) 89(5):442-453.
Fitzpatrick et al., “Expression of estrogen receptor-beta protein in rodent ovary,”Endocrinology(1999) 140(6):2581-2591.
Goldstein et al., “A pharmacological review of selective oestrogen receptor modulators,”Human Reproduction Update(2000) 6(3):212-224.
Green et al., “Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A,”Nature(1986) 320(6058):134-139.
Hall et al., “The multifaceted mechanisms of estradiol and estrogen receptor signaling,”Journal of Biological Chemistry(2001) 276(40):36869-36872.
Henke et al., “A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta,”Journal of Medicinal Chemistry(2002) 45(25):5492-5505.
Hurn et al., “Estrogen as a neuroprotectant in stroke,”Journal of Cerebral Blood Flow&Metabolism(2000) 20(4):631-652.
Kuiper et al., “Cloning of a novel receptor expressed in rat prostate and ovary,”Proceedings of the National Academy of Sciences of the USA(1996) 93(12):5925-5930.
Kuiper et al., “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta,”Endocrinology(1997) 138(3):863-870.
Levin, “Cell localization, physiology, and nongenomic actions of estrogen receptors,”Journal of Applied Physiology(2001) 91(4):1860-1867.
Levin, “Cellular Functions of the Plasma Membrane Estrogen Receptor,”Trends in Endocrinology&Metabolism(1999) 10(9):374-377.
McDonnell et al., “The mechanism of action of steroid hormone receptors,” Ch. 20, pp. 351-361,Principles of Molecular Regulation, Eds. Michael & Means. Totowa, NJ: Humana Press, 2000.
McDonnell, “Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen,”Journal of the Society of Gynecologic Investriction(2000) 7(1 Suppl):S10-S15.
McKenna et al., “Nuclear receptor coregulators: cellular and molecular biology,”Endocrine Review(1999) 20(3):321-344.
Mendelsohn et al., “The protective effects of estrogen on the cardiovascular system,”New England Journal of Medicine(1999) 340(23):1801-1811.
Meyers et al., “Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11, 12-tetrahydrochrysenes,”J. Med. Chem. (1999) 42(13):2456-2468.
Miller et al., “Constrained phytoestrogens and analogues as ERbeta selective ligands,”Bioorganic&Medicinal Chemistry Letters(2003) 13(14):2399-2403.
Monyer et al., “Glucose deprivation neuronal injury in cortical culture,”Brain Research(1989) 483(2):347-354.
Moggs et al., “Estrogen receptors: orchestrators of pleiotropic cellular responses,”EMBO Reports(2001) 2(9):775-781.
Monk et al., “Use of estrogens for the prevention and treatment of Alzheimer's disease,”Dementia&Geriatric Cognitive Disorders(2000) 11(1):1-10.
Paige et al., “Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta,”Proceedings of the National Academy of Sciences of the USA(1999) 96
Aulakh Charanjit S.
Milowsky Arnold S.
Patané Michael A.
Pepper Hamilton LLP
Wyeth
LandOfFree
6H-[1]benzopyrano[4,3-b]quinolines and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6H-[1]benzopyrano[4,3-b]quinolines and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6H-[1]benzopyrano[4,3-b]quinolines and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2786978